NO20051190L - Kronoterapeutiske diltiazem-formuleringer og administrering av disse - Google Patents

Kronoterapeutiske diltiazem-formuleringer og administrering av disse

Info

Publication number
NO20051190L
NO20051190L NO20051190A NO20051190A NO20051190L NO 20051190 L NO20051190 L NO 20051190L NO 20051190 A NO20051190 A NO 20051190A NO 20051190 A NO20051190 A NO 20051190A NO 20051190 L NO20051190 L NO 20051190L
Authority
NO
Norway
Prior art keywords
diltiazem
given
release
administration
sustained
Prior art date
Application number
NO20051190A
Other languages
English (en)
Norwegian (no)
Inventor
Paul J Maes
Kenneth Stephen Albert
Theophilus Jones Gana
Original Assignee
Biovail Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31978692&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20051190(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biovail Lab Inc filed Critical Biovail Lab Inc
Publication of NO20051190L publication Critical patent/NO20051190L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NO20051190A 2002-09-09 2005-03-04 Kronoterapeutiske diltiazem-formuleringer og administrering av disse NO20051190L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40887202P 2002-09-09 2002-09-09
PCT/US2003/027895 WO2004022038A1 (en) 2002-09-09 2003-09-09 Chronotherapeutic diltiazem formulations and the administration thereof

Publications (1)

Publication Number Publication Date
NO20051190L true NO20051190L (no) 2005-04-08

Family

ID=31978692

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20051190A NO20051190L (no) 2002-09-09 2005-03-04 Kronoterapeutiske diltiazem-formuleringer og administrering av disse

Country Status (10)

Country Link
US (2) US7348028B2 (xx)
EP (1) EP1545476A4 (xx)
JP (1) JP2006501261A (xx)
AU (1) AU2003270349A1 (xx)
CA (1) CA2496837A1 (xx)
MX (1) MXPA05002623A (xx)
NO (1) NO20051190L (xx)
NZ (1) NZ539174A (xx)
PL (1) PL375834A1 (xx)
WO (1) WO2004022038A1 (xx)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8778395B2 (en) * 2005-08-11 2014-07-15 Andrx Labs, Llc Diltiazem controlled release formulation and method of manufacture
KR101571198B1 (ko) 2009-03-18 2015-11-23 에보니크 룀 게엠베하 중성 비닐 중합체 및 부형제를 포함하는 코팅을 이용하는, 에탄올의 영향에 대한 내성을 갖는 제어 방출 제약 조성물
US20110311631A1 (en) * 2009-03-18 2011-12-22 Evonik Röhm Gmbh Controlled release pharmaceutical composition with resistance against the influence of ethanol employing a coating comprising a polymer mixture and excipients
US9603809B2 (en) 2011-03-23 2017-03-28 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US9119809B2 (en) 2011-03-23 2015-09-01 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9283214B2 (en) 2011-03-23 2016-03-15 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US11241391B2 (en) 2011-03-23 2022-02-08 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10292937B2 (en) 2011-03-23 2019-05-21 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
EP2688557B1 (en) 2011-03-23 2017-08-23 Ironshore Pharmaceuticals & Development, Inc. Methods and compositions for treatment of attention deficit disorder
US9498447B2 (en) 2011-03-23 2016-11-22 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10905652B2 (en) 2011-03-23 2021-02-02 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US8916588B2 (en) 2011-03-23 2014-12-23 Ironshore Pharmaceuticals & Development, Inc. Methods for treatment of attention deficit hyperactivity disorder
US8927010B2 (en) 2011-03-23 2015-01-06 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5364620A (en) * 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
IE56999B1 (en) * 1983-12-22 1992-03-11 Elan Corp Plc Pharmaceutical formulation
FR2623714B1 (fr) * 1987-11-26 1990-04-20 Ethypharm Sa Forme a liberation prolongee du diltiazem, et son medicament ainsi obtenu
US5344657A (en) * 1988-04-27 1994-09-06 Elf Sanofi Microbeads of diltiazem, a process for their manufacture and a substained-release pharmaceutical composition containing them
US5288505A (en) * 1991-06-26 1994-02-22 Galephar P.R., Inc., Ltd. Extended release form of diltiazem
US5229135A (en) * 1991-11-22 1993-07-20 Prographarm Laboratories Sustained release diltiazem formulation
US5376384A (en) * 1992-12-23 1994-12-27 Kinaform Technology, Inc. Delayed, sustained-release pharmaceutical preparation
US6524620B2 (en) * 1998-07-20 2003-02-25 Andrx Pharmaceuticals, Inc. Diltiazem controlled release formulation and method of manufacture
US7108866B1 (en) * 1999-12-10 2006-09-19 Biovall Laboratories International Srl Chronotherapeutic diltiazem formulations and the administration thereof

Also Published As

Publication number Publication date
CA2496837A1 (en) 2004-03-18
EP1545476A1 (en) 2005-06-29
WO2004022038A1 (en) 2004-03-18
PL375834A1 (en) 2005-12-12
NZ539174A (en) 2007-05-31
US20090118256A1 (en) 2009-05-07
EP1545476A4 (en) 2008-01-09
US7348028B2 (en) 2008-03-25
AU2003270349A1 (en) 2004-03-29
JP2006501261A (ja) 2006-01-12
US20040176352A1 (en) 2004-09-09
MXPA05002623A (es) 2005-05-05

Similar Documents

Publication Publication Date Title
NO20051190L (no) Kronoterapeutiske diltiazem-formuleringer og administrering av disse
CY1112260T1 (el) Σκευασματα υδροκωδονης ελεγχομενης απελευθερωσης
NO20073786L (no) Oralt biotilgjengelige CCI-779-formuleringer
NO20060991L (no) Feksofenadinsammensetning og fremgangsmate til fremstilling
DK1032605T3 (da) Polyanhydrider med terapeutisk anvendelige nedbrydningsprodukter
HUP0301591A2 (hu) Szabályozott hatóanyag-leadású hidrokodon-készítmények
EP1159964A3 (en) Compositions and methods for stimulating gastrointestinal motility
RS52577B (en) ONE-DAY OXYCODON FORMULATIONS
NO20062713L (no) 2,6 bisheteroaryl-4-aminopyrimidiner som adenosin reseptor antagonister
NO20045072L (no) Tablett med hoyt medikamentinnhold
JP2003531118A5 (xx)
HUP0004383A2 (hu) Hatóanyagként klodronátot és vivőanyagként szilíciumozott mikrokristályos cellulózt tartalmazó gyógyszerészeti készítmény
EP1576986A3 (en) Sustained-release tramadol formulations with 24-hour clinical efficacy
SE0101379D0 (sv) Komposition som hämmar utsöndring av magsyra
CA2005986A1 (en) Benzimidazole derivative with gastric acid inhibitory effect and process for its preparation
CY1106137T1 (el) Φαρμακευτικη συνθεση πepιλαμβανουσα λουμιρακοξιμπη
NO20052041L (no) Administrasjonsform for farmasoytisk aktive peptider med vedvarende frigivelse og fremgangsmate for fremstilling av denne
ATE430561T1 (de) Chronotherapeutische diltiazem formulierungen und deren verabreichung
NO20074175L (no) Fremgangsmater for kontroll av QT-intervall
RU2002100058A (ru) Кристаллические производные 1-метилкарбапенема
JP2000159790A5 (xx)
NO20032261L (no) Medisinske preparater
WO2007086079A3 (en) Sustained release dosage form of phenothiazine derivatives containing channelizer
NO991569L (no) Flytende alendronatforbindelser
WO2003099214A3 (en) Biguanide formulations

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application